CRO Partnership Announcement: Silexion Therapeutics has selected AMS Advanced Medical Services GmbH as its contract research organization to support upcoming Phase 2/3 clinical trials for SIL204, a siRNA candidate targeting KRAS-driven solid tumors, with trials expected to start in the first half of 2026.
Preclinical Success and Future Plans: SIL204 has shown promising preclinical results, achieving up to 97% inhibition in pancreatic cancer cells, and the upcoming trials will evaluate a dual-route administration strategy to enhance treatment efficacy against locally advanced pancreatic cancer.
SLXN
$2.61+Infinity%1D
Analyst Views on SLXN
Wall Street analysts forecast SLXN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLXN is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast SLXN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLXN is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.580
Low
12.00
Averages
12.00
High
12.00
Current: 2.580
Low
12.00
Averages
12.00
High
12.00
Litchfield Hills
Theodore O'Neill
Buy
initiated
$6
2025-12-15
New
Reason
Litchfield Hills
Theodore O'Neill
Price Target
$6
2025-12-15
New
initiated
Buy
Reason
Litchfield Hills analyst Theodore O'Neill initiated coverage of Silexion Therapeutics with a Buy rating and $6 price target. Silexion Therapeutics is targeting unmet need in KRAS-driven cancers and its siRNA platform takes a fundamentally different approach from current KRAS-targeted therapies, the analyst tells investors. The company is positioned to enter late-stage clinical development, with regulatory submission to the Israel Ministry of Health in Q4 followed by filings in Germany and the broader European Union in Q1, the analyst noted.
Maxim Group
Naz Rahman
Strong Buy
Maintains
$9 → $5
2025-03-20
Reason
Maxim Group
Naz Rahman
Price Target
$9 → $5
2025-03-20
Maintains
Strong Buy
Reason
Maxim lowered the firm's price target on Silexion Therapeutics to $5 from $9 and keeps a Buy rating on the shares after its Q4 results. The company is progressing with its SIL-204, an updated formulation of its prior LODER therapy, a KRAS targeting siRNA therapy for treating non-resectable, locally advanced pancreatic cancer, though the firm is reducing its price target due to the additional dilution from the recent capital raise and warrant exercises, the analyst tells investors in a research note.
About SLXN
Silexion Therapeutics Corp is an Israel-based oncology-focused biotechnology company. The Company is engaged in development of treatments for unsatisfactorily treated solid tumor cancers, which have the mutated KRAS oncogene. The KRAS gene is an oncogene that is involved in regulation of cell division as a result of its ability to relay external signals to the cell nucleus. Based on its research of refractory solid tumor cancers, it is developing a platform focused on the silencing of the KRAS oncogene using ribonucleic acid (RNA)-interference therapeutics. Its lead product candidate, SIL-204B, consists of locally administered small interfering RNAs (siRNA), in an extended-release formulation, as a preferred treatment of locally advanced pancreatic cancer patients, in combination with standard-of-care chemotherapy. Its clinical-stage pipeline is focused on treatment for pancreatic cancer (PC) tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
